SEC Form 4 · accession 0001209191-16-110835
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
James P Shaffer
Officer — Chief Business Officer
Period of report
Mar 23, 2016
Accepted (ET)
Mar 28, 2016 · 9:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $15.89 | Mar 23, 2016 | A | 60,699 | A | — | Mar 23, 2026 | Common Stock | 60,699 | 60,699 | D |
Explanation of responses
- F1The option will vest as to 25% of the option shares on March 23, 2017 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
- F2The option is subject to shareholder approval of an amendment to the Celladon Corporation 2013 Equity Incentive Plan. This is a voluntary early filing.